Press Releases Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Real-time Estimate Cboe BZX Other stock markets 08:14:03 16/05/2024 pm IST			5-day change	1st Jan Change
3.43 ^USD	+2.08%		+4.32%	+22.02%

14/05	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024
14/05	Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update	14/05	AQ
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day	08/05	AQ
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024	07/05	AQ
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update	27/03	AQ
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024	20/03	AQ
Cellectar Biosciences : Corporate Presentation - March 2024	18/03	PU
Cellectar Biosciences to Present at the 36th Annual Roth Conference	14/03	AQ
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03	AQ
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02	AQ
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study	30/01	AQ
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million	25/01	AQ
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient	23/01	AQ
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient	22/01	AQ
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	17/01	AQ
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data	16/01	AQ
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results	15/01	AQ
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results	12/01	AQ
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting	11/01	AQ
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia	08/01	AQ
Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024	03/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Press Releases

Filters